Of note, CCR6 is implicated in the IBD pathogenesis based on genome-wide associations studies (GWAS) [30], and clinically most important, treatment with an anti-CCL20 neutralizing antibody significantly reduced the severity of TNBS-induced colitis in mice, with concomitant reduction of CCR6-bearing infiltrated LP T-cells [31]. Here, CCL20 is linked to inflammatory bowel disease.